Health ❯ Pharmaceuticals ❯ Drug Development ❯ Clinical Research

Heart Disease

Amgen Reports Repatha Cuts First-Event Risk in Primary-Prevention Trial

Full results will be unveiled Nov. 8 at the AHA meeting to guide payer coverage and prescribing.